Transcriptomics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 6.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Transcriptomics Market Analysis
The transcriptomics market is expected to register a CAGR of 6.5% over the forecast period.
COVID-19 adversely impacted the life science and pharmaceutical industries in the beginning globally. Due to the high transmission rate and lack of treatment for COVID-19, the shutdown of research and academic institutes, supply chain disruptions, and trade restrictions, there has been a decline in the sales of reagents and consumables used for transcriptomics analysis. As per the annual report of 2020 by Nanostring Technologies Inc., the company witnessed a massive decline of 18% in its consumables segment compared to 2019. According to the 2020 results published by 10X Genomics Inc., the company observed a drop of 23.0% compared to 2019. However, the situation eventually improved. For instance, in June 2020, NanoString Technologies Inc. launched new solutions to study the immune response in COVID-19 disease research. The company launched the nCounter Host Response Gene Expression Panel and the COVID-19 Panel Plus spike-in to comprehensively analyze viral infection and immune response. Thus, the COVID-19 pandemic had a positive impact on the studied market.
In addition, the increasing research and development related to diagnostics and drug discovery in transcriptomics, increasing prevalence of chronic diseases such as cancer and neuromuscular disorder, and increase in applications of transcriptomics are actively affecting the growth of the studied market.
The product launches, expansions, collaboration and acquisitions by key market players is expected to drive the market growth significantly. For instance, in February 2020, Caris Life Sciences launched its newest addition to its comprehensive genomic profiling offering, MI Transcriptome, which enables Whole Transcriptome Sequencing (WTS). MI Transcriptome uses the capabilities of high-throughput sequencing to gain insight into the RNA profiles of patients' tumors and builds upon Caris' offering of the most comprehensive tumor profiling approach, which assesses DNA, RNA, and proteins to ensure patients receive the right therapies. Such product launches is likely to work in favor of the market growth.
Furthermore, in February 2020, Dovetail Genomics announced the global availability of its Dovetail HiChIP and Micro-C Kits. The companies are undertaking strategies to expand their customer base across the world which will augment the market growth.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, a lack of awareness regarding technology and stringent regulatory policies is likely to impede the market growth.
Transcriptomics Market Trends
This section covers the major market trends shaping the Transcriptomics Market according to our research experts:
Diagnostics and Disease Profiling is Expected to Witness Growth Over The Forecast Period
Transcriptomics has a variety of applications in diagnostics and disease analysis. In recent years, transcriptomics has shifted from strictly research applications to diagnostics and disease applications. Transcriptome analyses have been extensively used to understand the heterogeneity of tumors. Massively parallel single-cell RNA sequence analysis has emerged as a powerful method to understand the heterogeneity and to study cancer's rare cell populations through unsupervised sampling and modeling of transcriptional states in single cells.
The global spread of COVID-19 has bolstered the demand for a more comprehensive molecular understanding of the disease's pathophysiology. According to a research article titled "High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals" published in Frontiers in Immunology Journal in July 2021, the study had an average of 97.02% of sequences with perfect matching barcodes and a mean quality score of 35.59 ± 0.07, indicated that the sequencing was performed to a high level with low error. The average number of bases sequenced for each patient in the present study was 45 billion, which is an increase of more than 10 billion from the previous studies. Thus, the rising use of transcriptomics in the field of COVID-19 is likely to have a profound impact on the segment's growth.
Transcriptomics is the major tool for accelerating disease diagnostics processes. With the rapidly increasing global burden of chronic diseases such as cancer and diabetes, there is a need for advanced technologies for diseases and diagnostics. For instance, according to GLOBOCAN 2020 report, there were around 19.2 million new cases, and 9.9 cancer deaths were reported worldwide the world. This rapidly increasing patient pool is likely to positively influence the segment's growth.
Various market players operating in the transcriptomics market are constantly focusing on developing and introducing novel instruments and techniques in the arena of diseases and diagnostics. For instance, in August 2021 HTG Molecular Diagnostics, Inc. (HTG), announced the commercial launch of its HTG Transcriptome Panel in the United States and Europe. This panel uses the HTG EdgeSeq technology to measure almost 20,000 mRNA targets. The white paper published by the company indicated that the HTG Transcriptome Panel is repeatable and can be used to diagnose many cancers. Such advancements and launches are expected to bolster the segment's growth.
Hence, owing to the aforementioned factors, the segment is expected to attain good growth over the forecast period.
North America is Expected to Dominate the Transcriptomics Market Over The Forecast Period
North America is expected to dominate the market owing to factors such as the introduction of favorable government initiatives, increasing healthcare expenditure, the strong presence of industry players in the region, better healthcare infrastructure, awareness among people and healthcare industry stakeholders about available technologies, and the high concentration of market players in the United States.
The technological advancements, product approvals, launches, partnerships, and acquisitions by the key market players are projected to add growth to the market in the country. For instance, in January 2022, Illumina Inc. and Nashville Biosciences LLC, a subsidiary of Vanderbilt University Medical Center (VUMC), entered a multi-year agreement to accelerate drug development through large-scale genomics and the establishment of a clinical-genomic resource using Illumina's next-generation sequencing platforms. Such partnerships are expected to drive the growth of the transcriptomics market in the region.
Also, in March 2021, Rebus Biosystems launched its spatial transcriptomics analysis platform 'spatial omics' system, which is designed to give researchers a closer look at the output of individual cells across tissue samples. Such product launches will positively influence the market in the upcoming period. Additionally, in February 2021, Parse Biosciences launched Single Cell Whole Transcriptome Kit. The kit, previously available only through Parse's early access program, is now generally available to all researchers in North America. Therefore, owing to the above-mentioned factors, the growth of the studied market is anticipated in the North America Region.
Transcriptomics Industry Overview
The transcriptomics market is slightly fragmented due to many companies operating globally and regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some of the key players in the market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., GE Healthcare, Merck KGaA, 10x Genomics, Agilent Technologies Inc., BGI Genomics, Dovetail Genomics, Fluidigm Corporation, Illumina Inc., Natera Inc., PerkinElmer Inc., Promega Corporation, and Qiagen NV among others.
Transcriptomics Market Leaders
-
F. Hoffmann-La Roche Ltd
-
Thermo Fisher Scientific
-
Merck KGaA
-
GE Healthcare
-
Bio-Rad Laboratories
*Disclaimer: Major Players sorted in no particular order
Transcriptomics Market News
- In May 2022, BioSkryb Genomics launched the Early Access Program (EAP) for ResolveOME. This unified, single-cell workflow amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell.
- In January 2022, Parse Biosciences, a provider of single-cell sequencing solutions for researchers partnered with Research Instruments Pte Ltd to provide Parse's Evercode Whole Transcriptome Kits (WTKs), Cell Fixation Kits, and Nuclei Fixation Kits in Singapore and Southeast Asia.
Transcriptomics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Research and Development in Transciptomics
- 4.2.2 Increasing Prevalence of Chronic Illnesses
- 4.2.3 Increase in Applications of Transcriptomics
-
4.3 Market Restraints
- 4.3.1 Lack of Awareness Regarding the Technology
- 4.3.2 Stringent Regulatory Policies
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Technology
- 5.1.1 Microarray
- 5.1.2 Real-time Quantitative Polymerase Chain Reaction (Q-PCR)
- 5.1.3 Sequencing Technologies
-
5.2 By Product
- 5.2.1 Consumables
- 5.2.2 Instruments
- 5.2.3 Other Products
-
5.3 By Application
- 5.3.1 Diagnostics and Disease Profiling
- 5.3.2 Drug Discovery
- 5.3.3 Other Applications
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 10x Genomics
- 6.1.2 Agilent Technologies Inc.
- 6.1.3 BGI Genomics
- 6.1.4 Bio-Rad Laboratories Inc.
- 6.1.5 Dovetail Genomics
- 6.1.6 F. Hoffmann-La Roche AG
- 6.1.7 Fluidigm Corporation
- 6.1.8 GE Healthcare
- 6.1.9 Illumina Inc.
- 6.1.10 Merck KGaA
- 6.1.11 Natera Inc.
- 6.1.12 PerkinElmer Inc.
- 6.1.13 Promega Corporation
- 6.1.14 Qiagen NV
- 6.1.15 Thermo Fisher Scientific
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityTranscriptomics Industry Segmentation
As per the scope of the report, transcriptomics is the study of the entire set of RNA transcripts produced by the genome of any organism. The report highlights a detailed analysis of infectious disease diagnostics. The transcriptomics market is segmented by technology (microarray, real-time quantitative polymerase chain reaction (Q-PCR), and sequencing technologies), product (consumables, instruments, and other products), application (diagnostics and disease profiling, drug discovery, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| By Technology | Microarray | |
| Real-time Quantitative Polymerase Chain Reaction (Q-PCR) | ||
| Sequencing Technologies | ||
| By Product | Consumables | |
| Instruments | ||
| Other Products | ||
| By Application | Diagnostics and Disease Profiling | |
| Drug Discovery | ||
| Other Applications | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Transcriptomics Market Research FAQs
What is the current Global Transcriptomics Market size?
The Global Transcriptomics Market is projected to register a CAGR of 6.5% during the forecast period (2024-2029)
Who are the key players in Global Transcriptomics Market?
F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Merck KGaA, GE Healthcare and Bio-Rad Laboratories are the major companies operating in the Global Transcriptomics Market.
Which is the fastest growing region in Global Transcriptomics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Transcriptomics Market?
In 2024, the North America accounts for the largest market share in Global Transcriptomics Market.
What years does this Global Transcriptomics Market cover?
The report covers the Global Transcriptomics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Transcriptomics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Transcriptomics Industry Report
Statistics for the 2024 Transcriptomics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Transcriptomics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
